Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
This study has been withdrawn prior to recruitment.
Sponsors and Collaborators: Sheba Medical Center
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by: Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00323440
  Purpose

Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks and how colchicine helps, are questions not yet resolved. Elucidating the role of the inflammatory proteins is an important step towards the understanding of these questions. To date only small numbers of cytokines and inflammatory proteins have been studied individually. We propose to study a large number of these proteins in the RNA and protein levels addressing the interaction between them and the effect of colchicine on their expression.

Blood samples will be drawn from consenting patients in remission, during attacks, under and without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will donate control blood samples for the study. RNA will be produced from the neutrophils, and cytokines and various proteins' RNA expression will be determined. Major expressed proteins will be measured in the same samples and the results will be analyzed with regard to the activity of the disease, MEFV mutations and colchicine treatment status. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.


Condition
Familial Mediterranean Fever

Genetics Home Reference related topics: familial Mediterranean fever
MedlinePlus related topics: Fever
Drug Information available for: Colchicine Brucellosis
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission

Further study details as provided by Sheba Medical Center:

Estimated Enrollment: 80
Detailed Description:

Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks and how colchicine helps, are questions not yet resolved. Elucidating the role of the inflammatory proteins is an important step towards the understanding of these questions. To date only small numbers of cytokines and inflammatory proteins have been studied individually. We propose to study a large number of these proteins in the RNA and protein levels addressing the interaction between them and the effect of colchicine on their expression.

Blood samples will be drawn from consenting patients in remission, during attacks, under and without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will donate control blood samples for the study. RNA will be produced from the neutrophils, and cytokines and various proteins' RNA expression will be determined. Major expressed proteins will be measured in the same samples and the results will be analyzed with regard to the activity of the disease, MEFV mutations and colchicine treatment status. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • FMF patients, agreeing with diagnostic criteria, in attack or remission, under or without colchicine treatment.
  • Age 18 or older
  • Male or female
  • all ethnic groups arriving for treatment or routine follow up appointment
  • Written Consent to participate and donate blood for protein, RNA and DNA analyses.

Exclusion Criteria:

  • Younger than 18
  • Patients that use anti inflammatory medications, other than colchicine
  • Patients who in addition to FMF suffer from another acute infectious or inflammatory disease
  • Patients who in addition to FMF suffer from another chronic infectious or inflammatory or autoimmune disease.
  • Amyloidosis
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00323440

Locations
Israel
Sheba Medical Center
Tel Hashomer, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Avi Livneh, MD Sheba Medical Center
  More Information

Responsible Party: Sheba Medical Center ( Avi Livneh MD/ Head Medicine F )
Study ID Numbers: SHEBA-06-4126-AL-CTIL
Study First Received: May 7, 2006
Last Updated: May 18, 2008
ClinicalTrials.gov Identifier: NCT00323440  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
Familial Mediterranean fever
Inflammation
Attacks
Remission
RNA
Cytokines
Inflammatory proteins
MEFV
mutations
Colchicine
Treatment
microarray RNA analysis

Study placed in the following topic categories:
Bacterial Infections
Fever
Familial Mediterranean fever
Signs and Symptoms
Autoimmune Diseases
Genetic Diseases, Inborn
Colchicine
Familial Mediterranean Fever
Brucellosis
Gram-Negative Bacterial Infections
Inflammation

Additional relevant MeSH terms:
Immune System Diseases
Body Temperature Changes

ClinicalTrials.gov processed this record on January 14, 2009